Thursday, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) reported a fourth-quarter 2023 adjusted EPS loss of $(0.77), beating the consensus estimate of $(1.32) and lower than $(1.39) a year ago.
The company reported sales of $439.72 million, missing the consensus of $442.9 million.
The company achieved global net product revenues for Onpattro and Amvuttra for the fourth quarter of $79 million and $175 million, respectively, representing 10% of total TTR quarterly growth compared to Q3 2023.
It attained over 4,060 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with Onpattro or Amvuttra as of December 31, 2023.
The company reported global net product revenues for Givlaari and Oxlumo for the fourth quarter of $59 million and $33 million, respectively, representing 11% of total Ultra-Rare quarterly growth compared to Q3 2023.
It attained over 650 patients on commercial Givlaari and over 430 patients on commercial Oxlumo worldwide.
Investors are reacting to the fact that the company updated the timing for its HELIOS-B Phase 3 study of vutrisiran.
Alnylam announces updates to the statistical analysis plan …
Leave a Reply